Soleno Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	190.41	-	-	-	-
Cost of Revenue	2.7	-	-	-	-
Gross Profit	187.71	-	-	-	-
Selling, General & Admin	132.13	105.86	13.48	9.84	10.81
Research & Development	40.63	78.57	25.19	15.27	21.45
Other Operating Expenses	5.54	3.24	2.71	-0.71	-0.73
Total Operating Expenses	178.29	187.67	41.38	24.4	31.53
Operating Income	9.41	-187.67	-41.38	-24.4	-31.53
Interest Income	16.95	12.05	2.58	0.3	0.11
Interest Expense	-5.48	-0.23	-	-	-
Other Non-Operating Income (Expense)	-	-	-0.18	0.03	0.51
Total Non-Operating Income (Expense)	11.48	11.82	2.4	0.33	0.62
Pretax Income	20.89	-175.85	-38.99	-24.07	-30.91
Net Income	41.37	-351.7	-77.98	-24.07	-30.91
Net Income Attributable to Preferred Dividends	0.42	-	-	-	-
Net Income to Common	41.37	-351.7	-77.98	-24.07	-30.91
Shares Outstanding (Basic)	51	40	16	8	5
Shares Outstanding (Diluted)	52	40	16	8	5
Shares Change (YoY)	30.39%	143.61%	96.40%	57.90%	27.39%
EPS (Basic)	0.40	-4.38	-2.36	-2.87	-5.81
EPS (Diluted)	0.39	-4.38	-2.36	-2.87	-5.81
Shares Outstanding	52.29	45.7	31.68	8.16	5.32
Free Cash Flow	46.73	-69.31	-24.94	-20.79	-27.79
Free Cash Flow Per Share	0.89	-1.73	-1.51	-2.48	-5.23
Gross Margin	98.58%	-	-	-	-
Operating Margin	4.94%	-	-	-	-
Profit Margin	10.97%	-	-	-	-
FCF Margin	24.54%	-	-	-	-
EBITDA	11.43	-185.68	-39.43	-22.43	-29.57
EBITDA Margin	6.00%	-	-	-	-
EBIT	9.41	-187.67	-41.38	-24.4	-31.53
EBIT Margin	4.94%	-	-	-	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q